Phase 3 Study Confirms Clinical Equivalence for ABP 980 and Reference Trastuzumab
Complete phase 3 data show that a biosimilar almost beat reference trastuzumab (Herceptin) for the primary endpoint of pathologic complete response in patients with HER2-positive early breast cancer.